CASTLE BIOSCIENCES, INC. Financials Castle Biosciences, Inc.
Equities
CSTL
US14843C1053
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.53 USD | +5.85% |
|
+9.79% | -0.23% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 586.8 | 1,622 | 1,103 | 620.3 | 580.7 | 593.9 | - | - |
| Enterprise Value (EV) 1 | 513.1 | 1,212 | 773.4 | 361.7 | 337.6 | 384.3 | 409.6 | 387.4 |
| P/E ratio | 99.5 x | -124 x | -34.6 x | -9.12 x | -10.1 x | -9.61 x | -11 x | -19.1 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 11.3 x | 25.9 x | 11.7 x | 4.53 x | 2.64 x | 2.5 x | 2.31 x | 2.05 x |
| EV / Revenue | 9.89 x | 19.3 x | 8.22 x | 2.64 x | 1.54 x | 1.62 x | 1.59 x | 1.34 x |
| EV / EBITDA | 66.8 x | -200 x | -21.1 x | -5.8 x | -6.07 x | -6.42 x | -8.2 x | -11 x |
| EV / FCF | 84.4 x | 237 x | -34.4 x | -7.65 x | -17.5 x | -53.1 x | 312 x | 20.7 x |
| FCF Yield | 1.18% | 0.42% | -2.9% | -13.1% | -5.7% | -1.88% | 0.32% | 4.83% |
| Price to Book | 3.5 x | 3.06 x | 2.62 x | 1.54 x | 1.48 x | 1.58 x | 1.67 x | 1.66 x |
| Nbr of stocks (in thousands) | 17,074 | 24,156 | 25,730 | 26,352 | 26,911 | 27,587 | - | - |
| Reference price 2 | 34.37 | 67.15 | 42.87 | 23.54 | 21.58 | 21.53 | 21.53 | 21.53 |
| Announcement Date | 3/10/20 | 3/8/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 51.86 | 62.65 | 94.08 | 137 | 219.8 | 237.6 | 257.3 | 290 |
| EBITDA 1 | 7.686 | -6.07 | -36.67 | -62.31 | -55.65 | -59.85 | -49.95 | -35.12 |
| EBIT 1 | 7.328 | -6.542 | -40.08 | -72.86 | -67.98 | -69.36 | -63.88 | -38.99 |
| Operating Margin | 14.13% | -10.44% | -42.6% | -53.16% | -30.93% | -29.19% | -24.82% | -13.44% |
| Earnings before Tax (EBT) 1 | 5.349 | -10.2 | -40.01 | -68.9 | -57.36 | -61.23 | -55.63 | -34.47 |
| Net income 1 | 2.991 | -10.28 | -31.29 | -67.14 | -57.47 | -61.8 | -55.59 | -32.18 |
| Net margin | 5.77% | -16.42% | -33.26% | -48.99% | -26.15% | -26.01% | -21.6% | -11.1% |
| EPS 2 | 0.3455 | -0.5400 | -1.240 | -2.580 | -2.140 | -2.241 | -1.954 | -1.125 |
| Free Cash Flow 1 | 6.078 | 5.114 | -22.47 | -47.29 | -19.25 | -7.243 | 1.312 | 18.72 |
| FCF margin | 11.72% | 8.16% | -23.88% | -34.51% | -8.76% | -3.05% | 0.51% | 6.45% |
| FCF Conversion (EBITDA) | 79.08% | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | 203.21% | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/10/20 | 3/8/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 23.48 | 25.04 | 26.85 | 34.84 | 37.01 | 38.34 | 42.04 | 50.14 | 61.49 | 66.12 | 66.2 | 55.21 | 57.15 | 59.06 | 58.91 |
| EBITDA 1 | -10.72 | -13.72 | -11.35 | -10.88 | -8.275 | -19.99 | -15.1 | -5.268 | 6.577 | -2.434 | -12.2 | -16.6 | -15.3 | -14.33 | - |
| EBIT 1 | -11.81 | -15.17 | -21.95 | -22.66 | -21.69 | -22.83 | -31.52 | -21.16 | -9.64 | -5.658 | -11.11 | -20.53 | -19.23 | -18.47 | -20.64 |
| Operating Margin | -50.33% | -60.59% | -81.76% | -65.04% | -58.6% | -59.55% | -74.99% | -42.2% | -15.68% | -8.56% | -16.79% | -37.18% | -33.66% | -31.27% | -35.04% |
| Earnings before Tax (EBT) 1 | -11.79 | -15.16 | -24.49 | -3.605 | -20.25 | -20.56 | -29.19 | -18.76 | -6.873 | -2.541 | -8.942 | -18.49 | -17.26 | -16.51 | -19.05 |
| Net income 1 | -11.79 | -6.43 | -24.62 | -1.648 | -20.25 | -20.62 | -29.2 | -18.78 | -6.905 | -2.58 | -9.075 | -18.82 | -17.46 | -16.42 | -19.08 |
| Net margin | -50.23% | -25.68% | -91.7% | -4.73% | -54.71% | -53.78% | -69.47% | -37.45% | -11.23% | -3.9% | -13.71% | -34.09% | -30.54% | -27.8% | -32.39% |
| EPS 2 | -0.4700 | -0.2500 | -0.9700 | -0.0600 | -0.7700 | -0.7800 | -1.100 | -0.7000 | -0.2600 | -0.1000 | -0.3322 | -0.6844 | -0.6311 | -0.5900 | -0.6740 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 2/28/22 | 5/9/22 | 8/8/22 | 11/2/22 | 2/28/23 | 5/3/23 | 8/2/23 | 11/2/23 | 2/28/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 73.7 | 410 | 330 | 259 | 243 | 210 | 184 | 207 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 6.08 | 5.11 | -22.5 | -47.3 | -19.2 | -7.24 | 1.31 | 18.7 |
| ROE (net income / shareholders' equity) | 21% | -4.11% | -7.56% | -16.6% | -14.5% | -16% | -17.3% | -11.6% |
| ROA (Net income/ Total Assets) | 4.21% | -3.68% | -6.94% | -14.8% | -12.8% | -13.6% | -14.4% | -9.6% |
| Assets 1 | 71.08 | 279.5 | 451 | 455 | 450.3 | 456.1 | 387.4 | 335.2 |
| Book Value Per Share 2 | 9.830 | 22.00 | 16.40 | 15.30 | 14.60 | 13.60 | 12.90 | 13.00 |
| Cash Flow per Share 2 | 0.8100 | 0.5200 | -0.7200 | -2.170 | -0.2100 | -0.6700 | -0.5500 | 0.1900 |
| Capex 1 | 0.94 | 4.75 | 3.48 | 5.63 | 13.6 | 9.43 | 8.97 | 10 |
| Capex / Sales | 1.81% | 7.58% | 3.7% | 4.11% | 6.2% | 3.97% | 3.48% | 3.45% |
| Announcement Date | 3/10/20 | 3/8/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
21.53
USD
Average target price
33.11
USD
Spread / Average Target
+53.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.23% | 561M | |
| +1.69% | 12.8B | |
| -7.57% | 7.61B | |
| +3.22% | 5.41B | |
| +0.93% | 4.51B | |
| +8.48% | 4.49B | |
| +9.21% | 2.73B | |
| -13.87% | 2.02B | |
| -11.63% | 1.73B | |
| +3.45% | 1.64B |
- Stock Market
- Equities
- CSTL Stock
- Financials Castle Biosciences, Inc.
